Black Diamond Therapeutics Inc. has patented quinoxaline derivatives acting as fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer.
Amgen Inc. has described tricyclic-amido-bicyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Shenzhen Targetrx Biotechnology has disclosed epidermal growth factor receptor (EGFR) mutant and/or HER2 mutant inhibitors reported to be useful for the treatment of cancer.
Rappta Therapeutics Oy has divulged protein phosphatase 2A (PP2A) activators reported to be useful for the treatment of cancer, diabetes, neurodegeneration, heart failure, cardiac hypertrophy, autoimmune, chronic obstructive pulmonary and nonalcoholic fatty liver diseases among others.
Novartis AG and Les Laboratoires Servier SAS have identified proteolysis targeting chimeras (PROTACs) compounds comprising E3 ubiquitin ligase-binding moiety covalently bonded to Bcl-2-like protein 1 (BCL2L1)-targeting moiety through a linker reported to be useful for the treatment of cancer.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described pyrrolopyridazines acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer.
Yaoya Technology (Shanghai) Co. Ltd. has disclosed tyrosine-protein kinase BTK inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, lupus erythematosus, lupus nephritis, multiple sclerosis, asthma and Sjogren's syndrome.
RSS
